Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07510438

AVS Pulse Intravascular Lithotripsy™ (Pulse IVL™) to Open Vessels With Calcific Walls and Enhance Vascular Compliance and Remodeling for Coronary Artery Disease

A prospective, open-label, multi-site, FIH with up to fifteen (n=15) patients to assess the safety and preliminary effectiveness of the AVS Pulse Intravascular Lithotripsy™ System (Pulse IVL™ System) when used for the treatment of coronary artery disease.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Monash Health, Victorian Heart Hospital, Melbourne, Victoria, Australia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Key Inclusion Criteria:

  • ≥ 18 years of age
  • Subjects with native coronary artery disease
  • Left ventricular ejection fraction (LVEF) ≥ 35% within 6 months
  • The target lesion must be a single de novo coronary lesion
  • The target lesion stenosis of left anterior descending artery (LAD), right coronary artery (RCA), left circumflex artery (LCX), or ramus intermedius (RI), or of their branches with Stenosis of ≥70% and <100% or Stenosis ≥50% and <70% with evidence of ischemia
  • Lesion length must not exceed 44 mm

Key Exclusion Criteria:

  • Subject experienced an acute Myocardial Infarction (MI), either ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI) within 30 days prior to index procedure.
  • Subject has New York Heart Association (NYHA) class III or IV heart failure.
  • Subject has renal failure with serum creatinine >2.5 mg/dL, or chronic dialysis.
  • Subject has a previous stent in the target vessel implanted within last six months.
  • Unprotected LMCA diameter stenosis >30%.
  • Target lesion has a myocardial bridge.
  • Target vessel is excessively tortuous, defined as the presence of 2 or more bends >90 degrees or 3 or more bends >75 degrees.
  • Evidence of aneurysm in target vessel within 10 mm of the target lesion.
  • Target lesion in ostial location (LAD, RCA, LCX, or RI, within 5 mm of ostium) or in an unprotected LMCA.
  • Target lesion is a bifurcation with ostial diameter stenosis ≥30%.
  • Any previous stent within 10 mm of the target lesion.

Treatment and study plan

Pulse Intravascular Lithotripsy (Pulse IVL)

Device

The Pulse Intravascular Lithotripsy (Pulse IVL) System is used for the treatment of severely calcified stenotic de novo coronary arteries prior to stenting in patients with coronary artery disease.

Primary outcomes

  1. Achieve residual stenosis (<50%) in conjunction with stenting in the absence of major device related adverse events

    Time frame: Completion of study procedure

  2. Target lesion failure (TLF)

    Time frame: Within 30 days of study procedure

Study contacts

Contact information is provided by the study sponsor or research team.

Elise Gendreau

CONTACT

[email protected]

Elizabeth Galle

CONTACT

[email protected]

651-324-4790

Sponsors and collaborators

Lead sponsor

Amplitude Vascular Systems, Inc.

Industry

Registry information

Official study title

AVS Pulse Intravascular Lithotripsy™ (Pulse IVL™) to Open Vessels With Calcific Walls and Enhance Vascular Compliance and Remodeling for Coronary Artery Disease - A First-in-Human (FIH) Study

Acronym: POWER CAD I

Important dates

Study start
2026
Primary completion
2026
Study completion
2027
First posted
Apr 3, 2026
Registry last updated
May 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.